Celvia CC AS
Active Registry code 11673707
AS Tartu linn Registered 12 Aug 2009
Celvia CC AS is a AS based in Tartu linn, registry code 11673707, status: active. Main activity: Diagnostic imaging services and medical laboratory activities. According to EMTA, turnover for Q3 2026 was €212 665 with 47 employees.
Turnover
212 665 €
↓ 34.8% vs Q2 2026
State taxes
228 827 €
↑ 49.6% vs Q2 2026
Labour taxes
242 657 €
↑ 47.5% vs Q2 2026
Employees
47
±0 vs Q2 2026
Q3 2026 · data from the Tax and Customs Board (EMTA)
Position in the industry
- Turnover · Q3 2026 212 665 €above 98% of companiesindustry median 9 428 € · companies in the industry: 351
- Labour taxes per employee 5 163 €above 90% of companiesindustry median 2 177 € · companies in the industry: 1 696
- Revenue · 2025 2.8 mn €above 98% of companiesindustry median 20 811 € · companies in the industry: 3 373
- Net profit margin · 2025 21.0 %above 69% of companiesindustry median 8.3 % · companies in the industry: 2 759
Taxes and turnover
- Company
- Industry median
Industry: Human health activities (the EMTAK division of the main activity). Median: half of the industry is above, half below.
- Company
- Industry median
Industry: Human health activities (the EMTAK division of the main activity). Median: half of the industry is above, half below.
| Quarter | Turnover, € | State taxes, € | Labour taxes, € | Employees |
|---|---|---|---|---|
| Q3 2026 | 212 665 | 228 827 | 242 657 | 47 |
| Q2 2026 | 326 416 | 152 989 | 164 482 | 47 |
| Q1 2026 | 397 295 | 191 263 | 173 246 | 44 |
| Q4 2025 | 248 590 | 149 189 | 159 220 | 42 |
| Q3 2025 | 143 679 | 150 288 | 162 608 | 40 |
| Q2 2025 | 430 395 | 182 012 | 161 656 | 48 |
| Q1 2025 | 374 254 | 143 879 | 136 729 | 47 |
| Q4 2024 | 272 194 | 131 032 | 135 222 | 44 |
| Q3 2024 | 139 659 | 130 736 | 138 834 | 41 |
| Q2 2024 | 156 224 | 139 691 | 133 417 | 44 |
| Q1 2024 | 178 384 | 135 358 | 145 705 | 44 |
| Q4 2023 | 240 773 | 139 605 | 141 283 | 44 |
| Q3 2023 | 346 139 | 118 222 | 127 618 | 52 |
| Q2 2023 | 268 417 | 120 363 | 115 392 | 56 |
| Q1 2023 | 157 714 | 103 158 | 110 732 | 51 |
| Q4 2022 | 161 378 | 99 828 | 94 761 | 45 |
| Q3 2022 | 76 322 | 90 695 | 96 014 | 39 |
| Q2 2022 | 201 413 | 92 431 | 85 376 | 47 |
| Q1 2022 | 113 756 | 111 184 | 119 016 | 46 |
Labour taxes per employee per month
1 721 €
Turnover per employee in the quarter
4 525 €
Q3 2026 · calculated from EMTA data
Financials by year
- Company
- Industry median
Industry: Human health activities (the EMTAK division of the main activity). Median: half of the industry is above, half below.
- Company
- Industry median
Industry: Human health activities (the EMTAK division of the main activity). Median: half of the industry is above, half below.
- Company
- Industry median
Industry: Human health activities (the EMTAK division of the main activity). Median: half of the industry is above, half below.
- Company
- Industry median
Industry: Human health activities (the EMTAK division of the main activity). Median: half of the industry is above, half below.
| Year | Revenue, € | Net profit, € | Labour costs, € | Assets, € | Equity, € | Employees |
|---|---|---|---|---|---|---|
| 2025 | 2 811 620 | 590 786 | 1 528 034 | 2 125 948 | 1 081 276 | 35 |
| 2024 | 1 796 792 | 13 864 | 1 307 123 | 1 346 567 | 490 490 | 33 |
| 2023 | 1 481 706 | 33 866 | 1 266 643 | 1 476 282 | 476 626 | 35 |
| 2022 | 1 109 400 | 123 046 | 979 737 | 903 699 | 442 760 | 28 |
| 2021 | 1 196 230 | 65 314 | 979 761 | 945 932 | 319 714 | 28 |
| 2020 | 1 218 973 | 41 994 | 780 821 | 937 258 | 254 400 | 27 |
| 2019 | 452 355 | 20 212 | 554 445 | 456 209 | 206 462 | 20 |
| 2018 | — | — | — | — | — | 21 |
| 2017 | — | — | — | — | — | 22 |
| 2016 | — | — | — | — | — | 25 |
| 2015 | — | — | — | — | — | 33 |
| 2014 | — | — | — | — | — | 37 |
| 2013 | — | — | — | — | — | 31 |
| 2012 | — | — | — | — | — | 30 |
| 2011 | — | — | — | — | — | 30 |
| 2010 | — | — | — | — | — | 28 |
Figures from the company’s own (non-consolidated) balance sheet and income statement. A loss is shown with a minus sign.
Financial ratios for 2025
Net profit margin
21.0 %
Net profit / revenue
Return on equity (ROE)
54.6 %
Net profit / equity
Return on assets (ROA)
27.8 %
Net profit / assets
Equity ratio
50.9 %
Equity / assets
Debt ratio
49.1 %
Liabilities / assets
Current ratio
1.97
Current assets / current liabilities
Revenue per employee
80 332 €
Revenue / average full-time employees
Labour cost per employee per month
3 638 €
Labour costs / employees / 12 months (incl. employer taxes)
Annual reports
| Year | Period | Filed | Report | Documents |
|---|---|---|---|---|
| 2025 | 1 Jan 2025 – 31 Dec 2025 | 30 Jun 2026 | Company’s own · audited | e-Äriregister |
| 2024 | 1 Jan 2024 – 31 Dec 2024 | 30 Jun 2025 | Company’s own · audited | e-Äriregister |
| 2023 | 1 Jan 2023 – 31 Dec 2023 | 27 Jun 2024 | Company’s own · audited | e-Äriregister |
| 2022 | 1 Jan 2022 – 31 Dec 2022 | 30 Jun 2023 | Company’s own · audited | e-Äriregister |
| 2021 | 1 Jan 2021 – 31 Dec 2021 | 21 Jun 2022 | Company’s own · audited | e-Äriregister |
| 2020 | 1 Jan 2020 – 31 Dec 2020 | 29 Jun 2021 | Company’s own · audited | e-Äriregister |
| 2019 | 1 Jan 2019 – 31 Dec 2019 | 26 Jun 2020 | Company’s own · audited | e-Äriregister |
Board
- Nasdaq CSD SEKeeper of the share ledger · since 28 Sep 2017
- Andres SalumetsBoard member · since 12 Aug 2009
- Kaarel KrjutškovBoard member · since 13 Sep 2022
Right of representation
Any member of the management board may represent the public limited company in all transactions.
Owners
No owner information.
Beneficial owners
- Andres SalumetsDirect ownership · since 23 Jan 2025
- Kaarel KrjutškovDirect ownership · since 23 Jan 2025
Founders and other persons
- aktsiaselts Asper BiotechFounder · 31 000 € · 26 Jun 2009
- Aktsiaselts FertilitasFounder · 31 000 € · 26 Jun 2009
- Aktsiaselts Nova Vita KliinikFounder · 31 000 € · 26 Jun 2009
- aktsiaselts Tartu Biotehnoloogia ParkFounder · 62 000 € · 26 Jun 2009
- AS Kliinik EliteFounder · 31 000 € · 26 Jun 2009
- Bestenbalt OÜFounder · 31 000 € · 26 Jun 2009
- Eesti MaaülikoolFounder · 31 000 € · 26 Jun 2009
- EESTI TÕULOOMAKASVATAJATE ÜHISTUFounder · 31 000 € · 26 Jun 2009
- Osaühing RiistakastFounder · 31 000 € · 26 Jun 2009
- osaühing TBD-BiodiscoveryFounder · 31 000 € · 26 Jun 2009
- Tallinna ÜlikoolFounder · 31 000 € · 26 Jun 2009
- Tartu ÜlikoolFounder · 31 000 € · 26 Jun 2009
- AUDIITORBÜROO ELSS ASAudit firm · 29 Jun 2018
- Jaanus PikaniSupervisory board member · 1 Apr 2025
- Sander SalumetsSupervisory board member · 1 Apr 2025
- Piret OpmannSupervisory board member · 1 Jun 2026
- Omanikukonto: ANDRES SALUMETSShareholder · 12 878 € · 18 Feb 2026
- Omanikukonto: KAAREL KRJUTŠKOVShareholder · 8 916 € · 17 Aug 2026
Related companies
Activities (EMTAK)
- 86911Diagnostic imaging services and medical laboratory activities Main
- 72101Research and experimental development on natural sciences and engineering
Rulings
All rulings (PDF)| Number, date | Title | Deadline | State | Document |
|---|---|---|---|---|
| Ä 20046093 / 20 7 Oct 2025 |
Amendment entry | In force 7 Oct 2025 |
||
| Ä 20046093 / 19 8 Jul 2025 |
Amendment entry | In force 8 Jul 2025 |
||
| Ä 20046093 / M13 2 May 2025 |
Ruling to correct data outside an entry | 16 May 2025 | In force 2 May 2025 |
|
| Ä 20046093 / 18 4 Jul 2024 |
Amendment entry | In force 4 Jul 2024 |
||
| Ä 20046093 / 17 12 Mar 2024 |
Entry refused: deficiencies not eliminated | In force 1 Apr 2024 |
||
| Ä 20046093 / M12 31 Jan 2024 |
Ruling to eliminate deficiencies | 8 Mar 2024 | In force 11 Mar 2024 |
|
| Ä 20046093 / 16 13 Sep 2022 |
Amendment entry | In force 13 Sep 2022 |
||
| Ä 20046093 / M11 12 Sep 2022 |
Ruling to eliminate deficiencies | 2 Oct 2022 | Deficiencies eliminated 13 Sep 2022 |
|
| Ä 20046093 / 15 19 Jul 2022 |
Amendment entry | In force 19 Jul 2022 |
||
| Ä 20046093 / M10 3 May 2022 |
Ruling to correct data outside an entry | 17 May 2022 | Deficiencies eliminated 23 May 2022 |
|
| Ä 20046093 / 14 13 Jul 2020 |
Amendment entry | In force 13 Jul 2020 |
||
| Ä 20046093 / M9 7 Jul 2020 |
Ruling to eliminate deficiencies | 17 Jul 2020 | Deficiencies eliminated 8 Jul 2020 |
|
| Ä 20046093 / 13 22 Jan 2020 |
Amendment under Commercial Code § 525 (2) | In force 22 Jan 2020 |
||
| Ä 20046093 / M8 4 Jul 2018 |
Ruling to correct data outside an entry | 3 Aug 2018 | In force 4 Jul 2018 |
|
| Ä 20046093 / 12 17 Jan 2018 |
Amendment entry | In force 17 Jan 2018 |
||
| Ä 20046093 / 11 22 Dec 2017 |
Amendment entry | In force 22 Dec 2017 |
||
| Ä 20046093 / 10 4 Dec 2017 |
Amendment entry | In force 4 Dec 2017 |
||
| Ä 20046093 / 9 28 Sep 2017 |
Amendment entry | In force 28 Sep 2017 |
||
| Ä 20046093 / 8 21 Oct 2014 |
Amendment entry | In force 21 Oct 2014 |
||
| Ä 20046093 / 7 14 Feb 2013 |
Amendment entry | In force 14 Feb 2013 |
||
| Ä 20046093 / M7 12 Feb 2013 |
Ruling to eliminate deficiencies | 5 Mar 2013 | In force 12 Feb 2013 |
|
| Ä 20046093 / 6 12 Apr 2012 |
Amendment entry | In force 12 Apr 2012 |
||
| Ä 20046093 / M6 26 Mar 2012 |
Ruling to eliminate deficiencies | 10 Apr 2012 | In force 26 Mar 2012 |
|
| Ä 20046093 / 5 9 Jan 2012 |
Amendment entry | In force 9 Jan 2012 |
||
| Ä 20046093 / M5 2 Jan 2012 |
Ruling to eliminate deficiencies | 2 Mar 2012 | In force 2 Jan 2012 |
|
| Ä 20046093 / 4 25 Jul 2011 |
Amendment entry | In force 25 Jul 2011 |
||
| Ä 20046093 / 3 22 Jun 2011 |
Amendment entry | In force 22 Jun 2011 |
||
| Ä 20046093 / M4 27 May 2011 |
Ruling to eliminate deficiencies | 27 Jun 2011 | In force 27 May 2011 |
|
| Ä 20046093 / 2 8 Jul 2010 |
Amendment entry | In force 8 Jul 2010 |
||
| Ä 20046093 / M3 25 Jun 2010 |
Ruling to eliminate deficiencies | 15 Jul 2010 | In force 25 Jun 2010 |
|
| Ä 20046093 / M2 10 Jun 2010 |
Ruling to eliminate deficiencies | 1 Aug 2010 | In force 10 Jun 2010 |
|
| Ä 20046093 / M1 28 May 2010 |
Ruling to eliminate deficiencies | 20 Jun 2010 | In force 28 May 2010 |
|
| Ä 46093 12 Aug 2009 |
First entry | In force 12 Aug 2009 |
Sources: e-Äriregister and EMTA. Data updated 31 Oct 2026. Open at the source ↗ · Report an error in the data